文献速递神经肿瘤

SQAP通过抑制PI3K/Akt及损伤DNA修复增强胶质母细胞瘤放疗效果

Synergistic antitumor and radiosensitizing effects of α-sulfoquinovosyl-acylpropanediol (SQAP) via PI3K/Akt inhibition and DNA repair impairment in glioblastoma.
PubMed 文献 · J Neurooncol · 2025-08-11

本研究评估海洋化合物SQAP在胶质母细胞瘤(GBM)中的抗肿瘤与放疗增敏作用。体外实验显示SQAP抑制GBM细胞增殖而不损伤正常星形胶质细胞,联合放疗减少集落形成并增强细胞死亡;机制涉及抑制PI3K/Akt磷酸化、下调HIF-1α/VEGF及延迟DNA修复。小鼠颅内胶质瘤模型证实其疗效与安全性,支持SQAP作为GBM放疗辅助剂的潜力。

要点

  • SQAP抑制GBM细胞增殖,对正常星形胶质细胞无显著毒性。
  • SQAP联合放疗减少集落形成并增强细胞死亡,不依赖有丝分裂。
  • SQAP抑制PI3K/Akt、下调HIF-1α/VEGF并延迟放疗诱导的DNA修复。

核心结论

  • SQAP在GBM模型中通过抑制PI3K/Akt信号、抑制缺氧相关通路及损伤DNA修复发挥抗肿瘤和放疗增敏双重作用。
  • 研究支持SQAP作为GBM治疗中有前景的辅助药物。

研究设计与样本

  • 体外分析包括细胞活力、集落形成、免疫印迹、定量逆转录聚合酶链反应、免疫细胞化学及细胞死亡/增殖检测。
  • 体内疗效与安全性采用小鼠颅内胶质瘤模型评估。

主要发现

  • SQAP抑制GBM细胞增殖,同时不损伤正常星形胶质细胞。
  • SQAP联合放疗显著减少集落形成并增强细胞死亡,且不影响有丝分裂。
  • SQAP降低PI3K/Akt磷酸化并调节下游凋亡及细胞周期相关蛋白表达。
  • SQAP抑制HIF-1α和VEGF表达。
  • SQAP单独不引起DNA损伤,但延迟放疗诱导的DNA修复,表现为γH2AX表达延长及53BP1核表达减少。

临床怎么用

  • SQAP可能作为GBM放疗的辅助增敏剂,临床前数据支持进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiotherapy remains a key treatment modality for glioblastoma (GBM), but therapeutic resistance and radiation-induced toxicity severely limit its efficacy. Therefore, the development of novel, safe, and effective radiosensitizers is urgently needed. α-Sulfoquinovosylacylpropandiol (SQAP), a marine-derived compound, has demonstrated potent radiosensitizing effects in cancer cells by improving tumor oxygenation and interfering with DNA repair. However, its impact on GBM has not yet been investigated. This study aimed to evaluate the biological effects of SQAP on GBM cells and assess its potential as a radiosensitizer for future clinical application. METHODS: In vitro analyses-including cell viability, colony formation, immunoblotting, quantitative reverse transcription polymerase chain reaction, immunocytochemistry, and cell death/proliferation assays-were conducted to examine SQAP's mechanisms of action. In vivo efficacy and safety were evaluated using a murine intracranial glioma model. RESULTS: SQAP inhibited GBM cell proliferation while sparing normal astrocytes. In combination with radiotherapy, SQAP significantly reduced colony formation and enhanced cell death without affecting mitosis. SQAP decreased PI3K/Akt phosphorylation and modulated the expression of downstream apoptotic and cell cycle-related proteins. Additionally, SQAP suppressed HIF-1α and VEGF expression. Although SQAP alone did not cause DNA damage, it delayed radiotherapy-induced DNA repair, as shown by prolonged γH2AX expression and reduced 53BP1 nuclear expression. CONCLUSION: SQAP exerts both antitumor and radiosensitizing effects in GBM models by inhibiting PI3K/Akt signaling, suppressing hypoxia-related pathways, and impairing DNA repair. These findings support its potential as a promising adjunctive agent in GBM therapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nishiwaki T, Kudo U, Nakamura S, et al. Synergistic antitumor and radiosensitizing effects of α-sulfoquinovosyl-acylpropanediol (SQAP) via PI3K/Akt inhibition and DNA repair impairment in glioblastoma. J Neurooncol. 2025. PMID: 40788564. doi:10.1007/s11060-025-05194-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。